Starting Treatment With Agonist Replacement Therapies Follow-up Study

Completed

Conditions studied: Opioid Dependence

In brief

The purpose of the study is to conduct a follow-up of substance abuse patients (n=1,269) about 2 to 5 years since they were originally recruited from 8 substance abuse treatment clinics (located in 5 states) to participate in a prior clinical trial study called "START" (Starting Treatment with Agonist Replacement Therapies). The START Follow-up Study will be conducted over 5 years and will involve three follow-up interviews with START participants. The specific aims of the START Follow-up Study are as follows. 1. To determine longer-term outcomes of Suboxone versus methadone treatment received in the START 2. To investigate patient and treatment factors associated with post-START treatment access, utilization, and outcomes among Suboxone and methadone patients 3. To explore other correlates of the long-term outcomes among START patients.

Key facts

Study ID

NCT01592461

Run by

University of California, Los Angeles

People needed

877

Starts

2010-09-01

Expected to finish

2016-08-01

Last updated by the study team

2016-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be eligible to participate in the study, individuals must have participated in CTN-0027 START.

Where it is running

• Matrix Institute on Addictions — Los Angeles, California, United States
• Bi-Valley Medical Clinic, Inc. — Sacramento, California, United States
• BAART Programs — San Francisco, California, United States
• Hartford Dispensary — Hartford, Connecticut, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• CODA, Inc. — Portland, Oregon, United States
• NET Steps — Philadelphia, Pennsylvania, United States
• Evergreen Treatment Services — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.